Holen Sie sich die Stockscreener-App
18.06
0.44%
0.08
Handel nachbörslich:
17.77
-0.29
-1.61%
Schlusskurs vom Vortag:
$17.98
Offen:
$17.94
24-Stunden-Volumen:
1.63M
Relative Volume:
1.65
Marktkapitalisierung:
$1.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-183.79M
KGV:
-8.7284
EPS:
-2.0691
Netto-Cashflow:
$-131.84M
1W Leistung:
+2.27%
1M Leistung:
+14.67%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.25
$18.20
1-Wochen-Bereich:
$17.25
$19.62
52-Wochen-Spanne:
$14.62
$19.62
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
18.06 | 1.79B | 0 | -183.79M | -131.84M | -2.0691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
DFTX: Phase III data for DT120 in GAD and MDD expected in 2024, targeting major unmet needs - TradingView
DFTX: Three pivotal data readouts for GAD and MDD expected in 2024, with strong Phase II results - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.71 USD - Investing.com
Definium Therapeutics Announces New Employee Inducement Grants - National Today
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - marketscreener.com
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (2026-03-09) - Seeking Alpha
How Definium’s Widening 2025 Loss Will Impact Definium Therapeutics (DFTX) Investors - simplywall.st
Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX - MarketBeat
Equities Analysts Set Expectations for DFTX Q1 Earnings - Defense World
Q1 EPS Forecast for Definium Therapeutics Cut by Analyst - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation As Wider Full Year Loss Refocuses Investor Expectations - simplywall.st
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - simplywall.st
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics (DFTX) maps late-stage trials in anxiety, depression and autism - Stock Titan
[8-K] Definium Therapeutics, Inc. Reports Material Event | DFTX SEC FilingForm 8-K - Stock Titan
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates - Business Wire
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga España
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Wolfe Research - Defense World
Earnings Preview For Definium Therapeutics - Benzinga
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
DFTX: Wolfe Research Initiates Coverage with Outperform Rating | - GuruFocus
Definium Therapeutics to Participate at Upcoming Investor Conferences - The Globe and Mail
Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jefferies assigns 65–75% probability of best-in-class efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - MSN
Avoro Capital Advisors LLC Acquires 5 Million Shares in Definium Therapeutics Inc - GuruFocus
CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - The Joplin Globe
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Definium Therapeutics Inc-Aktie (DFTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Dec 26 '25 |
Sale |
13.15 |
25,791 |
339,072 |
778,477 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '25 |
Sale |
13.15 |
11,276 |
148,244 |
282,576 |
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):